Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Endocrine Disorders 1/2015

Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain

Zeitschrift:
BMC Endocrine Disorders > Ausgabe 1/2015
Autoren:
Elena Lundberg, Berit Kriström, Bjorn Jonsson, Kerstin Albertsson-Wikland, on behalf of the study group
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12902-015-0080-8) contains supplementary material, which is available to authorized users.

Competing interests

EL has no competing interest, has not received any commercial source of funding.
BK has received Umeå University Hospital Government Grants (ALF), lecture and/or consultation honoraria from Merck Serono, NovoNordisk, Pfizer and Sandoz. BJ was employed by Pilan Data Management AB until he died in February 2015. KA-W received an unrestricted research grant from Pharmacia/Pfizer until 2005. This investigator-initiated and sponsored trial, TRN 88–177 began in 1988. Kabi/Pharmacia supported the study by paying for monitoring of patients, the additional clinical costs and provided free drugs for patients receiving more than 33ug/kg/day. The study was also supported by grants from the Swedish Research Council (7509), the Swedish Foundation for Pediatric GH Research and the Foundation Växthuset for Children as well as University Hospital Government Grants (ALF) in Gothenburg and Umea. Kabi/Pharmacia/Pfizer has not had any influence on the collection, analysis and interpretation of these data or in the writing of this manuscript.

Authors’ contributions

The study was initiated (concept and design) in the 1980s by KAW, the PI who also served as local investigator for Gothenburg. Later in the 1990s, BK also became a local investigator for Umea. KAW, BK, EL made the clean file. BJ as biostatistician made all the statistical analyses. EL made the first draft. All authors made substantial intellectual contribution with analyses, interpretation of data and revising the manuscript for important intellectual content. All authors have given approval for the final version to be published.

Abstract

Background

Responsiveness to GH treatment can be estimated by both growth and ∆IGF-I. The primary aim of the present study was to investigate if mimicking the physiological increase during puberty in GH secretion, by using a higher GH dose could lead to pubertal IGFs in short children with low GH secretion. The secondary aim was to explore the relationship between IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio and gain in height.

Methods

A multicentre, randomized, clinical trial (TRN88-177) in 104 children (90 boys), who had received GH 33 μg/kg/day during at least 1 prepubertal year. They were followed from GH start to adult height (mean, 7.5 years; range, 4.6–10.7). At onset of puberty, children were randomized into three groups, to receive 67 μg/kg/day (GH67) given once (GH67x1; n = 30) or divided into two daily injection (GH33x2; n = 36), or to remain on a single 33 μg/kg/day dose (GH33x1; n = 38). The outcome measures were change and obtained mean on-treatment IGF-ISDS, IGFBP3SDS and IGF-I/IGFBP3 ratioSDS during prepuberty and puberty. These variables were assessed in relation to prepubertal, pubertal and total gain in heightSDS.

Results

Mean prepubertal increases 1 year after GH start were: 2.1 IGF-ISDS, 0.6 IGFBP3SDS and 1.5 IGF-I/IGFBP3ratioSDS. A significant positive correlation was found between prepubertal ∆IGFs and both prepubertal and total gain in heightSDS. During puberty changes in IGFs were GH dose-dependent: mean pubertal level of IGF-ISDS was higher in GH67 vs GH33 (p = 0.031). First year pubertal ∆IGF-ISDS was significantly higher in the GH67vs GH33 group (0.5 vs −0.1, respectively, p = 0.007), as well as ∆IGF-ISDS to the pubertal mean level (0.2 vs −0.2, p = 0.028). In multivariate analyses, the prepubertal increase in ‘∆IGF-ISDS from GH start’ and the ‘GH dose-dependent pubertal ∆IGF-ISDS’ were the most important variables for explaining variation in prepubertal (21 %), pubertal (26 %) and total (28 %) gain in heightSDS.

Trial registration

TRN 88–177, not applicable 1988.

Conclusion

The dose-dependent change in IGFs was related to a dose-dependent pubertal gain in heightSDS. The attempt to mimic normal physiology by giving a higher GH dose during puberty was associated with both an increase in IGF-I and a dose-dependent gain in heightSDS.
Zusatzmaterial
Additional file 1: Table S1. Baseline characteristics according to randomization group: at birth, at GH start and at study start. Table S2. Baseline characteristics according to gender and infancy–childhood transition (ICT): at birth, at GH start, at study start and at adult height. (PDF 222 kb)
12902_2015_80_MOESM1_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Endocrine Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise